EGAGenomicsIllumina Genome Analyzer IIx;https://ega-archive.org/datasets/EGAD00001001107154EGA dataset EGAD00001001107EGA<h4>Purpose</h4>Tailoring cancer treatment to tumor molecular characteristics promises to make personalized medicine a reality. However, reliable genetic profiling of archived clinical specimens has been hindered by limited sensitivity and high false-positive rates. Here, we describe a novel methodology, MMP-seq, which enables sensitive and specific high-throughput, high-content genetic profiling in archived clinical samples.<h4>Experimental design</h4>We first validated the technical performance of MMP-seq in 66 cancer cell lines and a Latin square cross-dilution of known somatic mutations. We next characterized the performance of MMP-seq in 17 formalin-fixed paraffin-embedded (FFPE) clinical samples using matched fresh-frozen tissue from the same tumors as benchmarks. To demonstrate the potential clinical utility of our methodology, we profiled FFPE tumor samples from 73 patients with endometrial cancer.<h4>Results</h4>We demonstrated that MMP-seq enabled rapid and simultaneous profiling of a panel of 88 cancer genes in 48 samples, and detected variants at frequencies as low as 0.4%. We identified DNA degradation and deamination as the main error sources and developed practical and robust strategies for mitigating these issues, and dramatically reduced the false-positive rate. Applying MMP-seq to a cohort of endometrial tumor samples identified extensive, potentially actionable alterations in the PI3K (phosphoinositide 3-kinase) and RAS pathways, including novel PIK3R1 hotspot mutations that may disrupt negative regulation of PIK3CA.<h4>Conclusions</h4>MMP-seq provides a robust solution for comprehensive, reliable, and high-throughput genetic profiling of clinical tumor samples, paving the way for the incorporation of genomic-based testing into clinical investigation and practice.High-throughput detection of clinically relevant mutations in archived tumor samples by multiplexed PCR and next-generation sequencing.Bourgon Richard R, Lu Shan S, Yan Yibing Y, Lackner Mark R MR, Wang Weiru W, Weigman Victor V, Wang David D, Guan Yinghui Y, Ryner Lisa L, Koeppen Hartmut H, Patel Rajesh R, Hampton Garret M GM, Amler Lukas C LC, Wang Yulei YF20P5_11, benign mucous membrane pemphigoid, ocular pemphigoid, matrix metalloproteinase 7 activity, Metalloproteinases, metalloproteinase pump-1, PUMP, uterine metalloendopeptidase activity, Cell Lines, Matrix, putative metalloproteinase activity, Metalloproteinase, cicatricial pemphigoid with ocular involvement, Cell, PUMP-1 activity, ocular pemphigus, matrix metalloproteinase pump 1, benign mucosal pemphigoid, MMP 7, MMPs, putative (or punctuated) metalloproteinase-1 activity, PUMP-1 proteinase activity, Matrix Metalloproteinase, Line, MMP, Cell., benign mucous membrane pemphigoid with ocular involvement, F20P5.11, matrix metalloproteinase, matrin activity, LinesF20P5_11, benign mucous membrane pemphigoid, ocular pemphigoid, matrix metalloproteinase 7 activity, Metalloproteinases, metalloproteinase pump-1, PUMP, uterine metalloendopeptidase activity, Cell Lines, Matrix, putative metalloproteinase activity, Metalloproteinase, cicatricial pemphigoid with ocular involvement, Cell, PUMP-1 activity, ocular pemphigus, matrix metalloproteinase pump 1, benign mucosal pemphigoid, MMP 7, MMPs, putative (or punctuated) metalloproteinase-1 activity, PUMP-1 proteinase activity, Matrix Metalloproteinase, Line, MMP, Cell., benign mucous membrane pemphigoid with ocular involvement, F20P5.11, matrix metalloproteinase, matrin activity, Linespolymerase chain reaction., Anchored, Anchored Polymerase Chain Reaction, Malignant Neoplasm, Reactions, Nested, Malignancy, Nested Polymerase Chain Reaction, Neoplasms, Benign Neoplasm, Inverse Polymerase Chain Reaction, Benign Neoplasms, Polymerase Chain Reactions, Cancers, Tumor, Inverse, Malignant, Malignant Neoplasms, Mutations, Neoplasias, Inverse PCR, Benign, Reaction, Neoplasm, Nested PCR, Malignancies, Anchored PCR, Polymerase Chain, other neoplasm, Neoplasia, PCR, Cancer, TumorsUVO Gene Mutation, Experimental Designs, Ras, l(1)G0098, H. pylori Positive, Materials, dP60, Adjustments, endometrium neoplasm (disease), Vps34, let it be made, Biochemical Pathway, Tumor, Ras-1, ERBB2 Amplification, Positive Charge, PI-3 kinase, ras, RET/PTC Rearrangement, c-ras2, Hepatitis C Virus RNA Positive, p53 Mutation, PGR Positive, AGM7, Kinase, SEQ, Methylated MGMT Promoter, F, ERA Positive, G Protein Subunit Alpha q Gene Mutation, IDH Gene Mutation, CD324 Gene Mutation, Molecular, Hepatitis B Virus Core Antibody Positive, c-KIT Positive, Flavoprotein Subunit of Complex II Positive, B7H1 Positive, BEK Gene Mutation, procedures, node-positive, Cadherin 1 Gene Mutation, ESTRB Positive, XH2 Gene Mutation, D17Mit170, PI3Kgamma, Based, ENDMC, Catenin Beta 1 Gene Mutation, ER Beta Positive, Hepatitis B DNA Positive, Telomerase Reverse Transcriptase Gene Promoter Mutation, ATP - 1-phosphatidyl-1D-myo-inositol 3-phosphotransferase activity, Methylated MGMT Gene Promoter, Data Reporting, Tumors, Ras2, Human Immunodeficiency Virus Positive, KGFR Gene Rearrangement, Ras1, Research Methodology, c-erbB2 Gene Amplification, rea, B-RAF Gene Rearrangement, DNA catabolism, Anti-HBc Positive, p50alpha, Hepatitis B Virus Surface Antibody Positive, Tl3, Tl2, Estrogen Receptor Alpha Positive, DmelCG5373, Experimental, Benign, tumor of Endometrium, SDHIP Positive, type-1 PI3K, Technics, FGFR-2 Gene Rearrangement, FLT2 Gene Mutation, FGFR-1 Gene Rearrangement, Problem Formulation, RET Gene Rearrangement, BcDNA:RE36103, Carcinomas, CG11621, NRAS Gene Mutation, ECAD Gene Mutation, Hras-1, Predominant, Benign Neoplasms, Dm Ras1, EST2 Promoter Mutation, Present, ESR Positive, PDCD1L1 Positive, Malignant Neoplasms, Formulations, APDS, RasI, Positive EBV Serum Test, IDH Gene Family Mutation, Theranostics, N-RAS Gene Mutation, HER2/Neu Amplification, KRAS Gene Mutation, Detected, Expression of PD-L1, Harvey-ras, Inositide, SDHF Positive, Nuclear Receptor Subfamily 3 Group A Member 2 Positive, BRCA1-Associated Protein 1 Gene Mutation, Neoplasms, CDHE Gene Mutation, Traverse, MANUF, Phosphatidylinositol, DRAS1, Succinate Dehydrogenase [Ubiquinone] Iron-Sulfur Subunit, Hepatitis B Virus Surface Antigen Positive, endometrial neoplasm, Dras2, Dras1, PIK3, Pi3Kp60, D-Ras, Sources, Phosphatidyl, dPI3K, Precision, IMPdH, G Protein Subunit Alpha 11 Gene Mutation, Ha-ras, Technique, Dras, B7-H Positive, Cadherin-Associated Protein, Clinical, MGMT Gene Methylation, Hepatitis B Core Antibody Positive, raspberry/impd, Malignant Neoplasm Treatment, Pi3Kp110, Ras[V12], Metalloproteinase, EK3-4, Research Strategy, BEK Gene Rearrangement, DRas, Neoplasias, RET Rearrangement, Dmras64B, RAD54 Homolog Gene Mutation, genome, benign mucous membrane pemphigoid with ocular involvement, HER-2 Gene Amplification, MCM, Predictive, Including, Cpk, p85-ALPHA, New, Positive EBV Test, Malignant Neoplasm, cou, Archived, PR Positive, type III phosphoinositide 3-kinase activity, Hepatitis B Surface Protein Antigen Positive, Estrogen Receptor Positive, Phosphoglycerides, Personalized, cpk, Research Strategies, PI3K-92E/Dp110, B-RAF1 Gene Rearrangement, PIK3C1, DmelCG1167, Lr, ATRX, MT, Inositol Phosphoglycerides, BRAF Gene Rearrangement, clinical, FLG Gene Mutation, PAX8 Rearrangement, Androgen Receptor Positive, HGFR Gene Amplification, ESR1 Positive, MET Gene Amplification, c-MET Gene Amplification, Endometrial Neoplasm, ER-Alpha Positive, RAS85D, Methylated MGMT, Dmras85D, Phospholipids, l(1)9Eb, ocular pemphigoid, ERG Rearrangement, HBsAg Positive, Research Designs, Deaminations, Dilute, malignant tumor, TERT Gene Promoter Mutation, Data Adjustment, Ret Proto-Oncogene Rearrangement, DmVps34, Specific, IDH Mutation, PI3K_68D, PI3K-92D, 1p/19q Co-deletion, SDHA Positive, Q Polypeptide Gene Mutation, Dmp110, Succinate Dehydrogenase [Ubiquinone] Flavoprotein Subunit, matrix metalloproteinase, Strategy, Neoplasia, Main, Estrogen Receptor 2 Positive, Endometrial Cancer, XNP Gene Mutation, O-6-Methylguanine-DNA Methyltransferase Gene Promoter Methylation, CG5373, ER Positive, ATVPS34, v-Ets Erythroblastosis Virus E26 Oncogene Like Gene Rearrangement, Feature, clinical data, Characterization, Fresh Specimen, Technic, PtdIns, endometrial tumour, HRAS1 Gene Mutation, CG11485, G-ALPHA-q Gene Mutation, BAP1 Gene Mutation, Techniques, PHOSPHATIDYLINOSITOL 3-KINASE, DmelCG2699, Make, F8A5.4, p110alpha, v-Erb-B2 Avian Erythroblastic Leukemia Viral Oncogene Homolog 2 Gene Mutation, Detection, D-Ras1, TP53, Abnormal, gene expression, Group, Estrogen Receptor Beta Positive, Endometrium Carcinomas, Identification, Endometrium Cancers, endometrium tumour, l(1)G0436, catalyst activity, DOG1 Positive, hypoplasia, Groups, PI[[3]]K, ETV Family Gene Rearrangement, Ets Variant Family Rearrangement, T1, FLT2 Gene Rearrangement, Phosphatidyl Inositol, genetic, Rearrangement identified, Panel Device, Novel, FGFR3 Gene Rearrangement, ECT1 Gene Mutation, Estrogen Receptor 1 Positive, tumor of the endometrium, Fibroblast Growth Factor Receptor 2 Gene Mutation, IDH Family Mutation, CD333 Gene Rearrangement, Hotspot, Research Techniques, Anti-Hepatitis C Antibody Positive, GRB1, ATRX Gene Mutation, Endometrial Carcinoma, ERG Gene Rearrangement, P110DELTA, Ki-ras, FFPE, HER2 Gene Mutation, somatic, results, PUMP-1 activity, dPIK, Gene Expression, Hepatitis B Surface Antibody Positive, HIV Positive, MMP, Phosphoglyceride, dRas1, F20P5.11, Problem, HIV positive, ras-2, 1p/19q Codeletion, POSITIVE, Guanine Nucleotide Binding Protein (G Protein), F20P5_11, Yes, Rapidly, DmelCG1799, SDH2 Positive, l(1)G0238, C-ras1, ERBB2 Gene Mutation, PI3K 68_D, Features, Endometrial Cancers, C-ras2, Endometrium, l(1)G0002, l(1)G0482, p110D, Specificity and Sensitivity, Expressed, Purpose, c-H-ras, ER-Beta Positive, Inositide Phospholipids, Base, HRAS Gene Mutation, molecular pathway, Harvey Rat Sarcoma Viral Oncogene Homolog Gene Mutation, droPIK57, BRAF Rearrangement, CDH1 Gene Mutation, RasV12, PI3K92E, Kras2, Matrix, Anti-HBs Positive, c-erbB2 Gene Activation, Malignant, MALIGNANT_CELLS, Fp Positive, Fibroblast Growth Factor Receptor 1 Gene Rearrangement, Scoring Methods, p60, DNA breakdown, OGD Gene Mutation, Anti-HBcAb Positive, Hep C RNA Positive, PHOSPATIDYLINOSITOL 3-KINASE, Low, neoplasm of the endometrium, tiny, endometrial cancer, Inositide Phospholipid, CD274 Antigen Positive, Performance, Epithelial Gene Mutation, MET Proto-Oncogene, DILUTING, p21B, Phospholipid, Scoring, Research, SWS Gene Mutation, TAOS2 Positive, Transphosphorylase, Methylguanine-DNA Methyltransferase Gene Promoter Methylation, Neuroblastoma RAS Viral Oncogene Homolog Gene Mutation, H-ras Gene Mutation, PI3K-68D, ETV Gene Rearrangement, Cancer Therapeutic Procedure, Cancer Cell, Clients, p85, CD332 Gene Rearrangement, Matrix Metalloproteinase, Error Source, Ets Variant Gene Family Rearrangement, Sensitivity, HER2 Gene Amplification, Characteristics, Strategies, ras-l, Anti-Hepatitis C Virus Antibody Positive, CTNNB Gene Mutation, progesterone receptor positive, RASH1 Gene Mutation, Carcinoma of Endometrium, small, l(1)G0056, Anti-Hepatitis B Virus Core Antibody Positive, CG9375, malignant, K-ras, Vps34p, Manufacturer, malignant neoplasm of endometrium, fs(3)05703, ATP:1-phosphatidyl-1D-myo-inositol 3-phosphotransferase activity, File in Error, vps34, NR3A2 Positive, MGMT Gene Promoter Methylation, dp110, TMEM16A Positive, PI3CG, AI929937, Testing., Catenin Beta-1 Gene Mutation, MGMT Methylation, AR Positive, PI-3-K, Cross, FMS-Like Tyrosine Kinase 2 Gene Mutation, HIV Positivity, Mast/Stem Cell Growth Factor Receptor Kit Positive, Endometrial Carcinomas, Kinases, class III, FGFR-2 Gene Mutation, Calcium-Dependent Adhesion Protein, Tumor cells, MMPs, Data, tumour of the endometrium, tumor of endometrium, HBs Antigen Positive, CD274 Molecule Positive, methodology, GTPase Gene Mutation, Anti-HBsAb Positive, RAS, Beta Gene Mutation, Across, Design, Error Sources, Progesterone Receptor Positive, Concurrency, BcDNA:LD15217, Genetic Hotspot, fiat, FGFBR Gene Rearrangement, VPS34, 11621, Mutations, p110-alpha, benign mucosal pemphigoid, Method, HCV Antibody Positive, Nuclear Receptor Subfamily 3 Group A Member 1 Positive, Dilution, Erg-3 Gene Rearrangement, CD332 Gene Mutation, Ha-ras Gene Mutation, EXPRESSED, HRas Proto-Oncogene, Dp60, benign mucous membrane pemphigoid, TRT Promoter Mutation, PI3K_59F, Maker, Matched Group, GAQ Gene Mutation, Met Proto-Oncogene (Hepatocyte Growth Factor Receptor) Gene Amplification, Matched, Pathways, composition, PI3-kinase activity, FGFR1 Gene Rearrangement, PD-L1+, cicatricial pemphigoid with ocular involvement, Fast, NEU Gene Mutation, allergic reaction, v-raf Murine Sarcoma Viral Oncogene Homolog B1 Gene Rearrangement, MCAP, Inositol Phospholipids, FGFR3 Gene Mutation, SDHB Positive, K-RAS Mutation, Reporting, Familiar, Rapid, CD331 Gene Rearrangement, PI3K 68D, Medicine, Cancer of Endometrium, C-HA-RAS1 Gene Mutation, MET Amplification, ZNF-HX Gene Mutation, ATP Phosphotransferases, Comprehensive, ERBB2 Gene Amplification, CG1799, Beta Catenin Gene Mutation, dVps34, Pathway, RAS2, Research Technic, RAS1, familial, Frozen Tissue, Malignant Neoplasm Therapy, Simultaneous, CG2699, Research Proposal, Alpha 11 Gene Mutation, matrix metalloproteinase pump 1, CD331 Gene Mutation, C530050K14, ERB Positive, dil., Cadherin, primary malignant neoplasm of endometrium, dRas85D, JKT4 Gene Rearrangement, ras1, PI3KA, CMC1 Gene Mutation, ras2, DNA degradation, P53 Gene Mutation, matrix metalloproteinase 7 activity, Guanine Nucleotide-Binding Protein, PAX8 Gene Rearrangement, content, NR3A1 Positive, Malignant Cell, Keratinocyte Growth Factor Receptor Gene Rearrangement, HER2 Amplification, DmelCG4141, F8A5_4, Genomic, CD333 Gene Mutation, Positive Epstein-Barr Virus Test, Characterized, Phosphoinositides, Material, PI3KBETA, FGFBR Gene Mutation, PUMP-1 proteinase activity, TCS1 Promoter Mutation, other neoplasm, Data Adjustments, BFGFR Gene Mutation, Hras1, Fresh, Clinical Batch, False, Potential, FRESH, dRas, Matched Groups, CG1167, HCV RNA Positive, COINCIDENT, H-ras, DRas2, anticancer therapy, putative metalloproteinase activity, IMPDH, LD06825, ER+, ft., sequenceNumber, Receptor Tyrosine Kinase Gene Amplification, Adjustment, FGFR1 Gene Mutation, p55 Gene Rearrangement, FLG Gene Rearrangement, dVps34/PI3K59F, sensitive, PDCD1LG1 Positive, deamination, PI3K-dp110, Kras-2, anon-92Ed, Latin Square Study, class I, ras 1, ETV Rearrangement, androgen receptor positive, Endometrial cancer, HBs Positive, Individualized, Positive Number, positive test result, v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog Gene Mutation, GNAQ Gene Mutation, PD-L1 Positive, Solution, P110BETA, DRas85D/Ras, neoplasm of endometrium, CTNNB1 Gene Mutation, Endometrial, FGFR2 Gene Rearrangement, PI3K21B, ANO1 Positive, putative (or punctuated) metalloproteinase-1 activity, RAD54 Gene Mutation, Panel, Expression, constitutitional genetic, Cancer, CD117 Positive, FGFR2 Gene Mutation, Helicobacter pylori Positive, AA414921, Predictive Medicine, class II, ESRB Positive, Matching, compositionality, D-ras-1, PI(3)K, E(faf), malignant endometrial neoplasm, Positive Finding, CWS5, GNA11 Gene Mutation, Neoplasm, endometrial Ca, S35097, Hepatocyte Growth Factor Receptor Gene Amplification, primary cancer, Cancer Treatment, underdeveloped, HBcAb Positive, Metalloproteinases, Match, Tumor Protein p53 Gene Mutation, Specificity, LATIN SQUARE, Theranostic, Cancers, IP Positive, Research Technics, DmelCG11621, Hepatitis B Surface Antigen Positive, Anti-HCV Antibody Positive, Manufacturing, N-RAS Mutation, FLT-2 Gene Mutation, ETS Transcription Factor ERG Gene Rearrangement, caPI3K, CLOVE, Formalin-Fixed Paraffin-Embedded, P-Health, Error, IMD14, CEK Gene Mutation, structure, Bra, Alpha-11 Gene Mutation, endometrium tumor, hereditary, Chromatin Remodeler Gene Mutation, Extensive, Ras1/RAs85D, Archival, Research Technique, Fibroblast Growth Factor Receptor 1 Gene Mutation, Problem Formulations, Individualized Medicine, Hepatitis C Viral RNA Positive, FLT-2 Gene Rearrangement, PI3K, c-rasHa, Dp110, E(sev)3C, JKT4 Gene Mutation, AR+, KRAS Mutation, composed of, ESR-Beta Positive, Fibroblast Growth Factor Receptor 2 Gene Rearrangement, FGFR-3 Gene Rearrangement, IMD36, KGFR Gene Mutation, phosphatidylinositol 3-kinase activity, Experimental Design, estrogen receptor positive, me75, RTK, Pi3K92D, CG4141, metalloproteinase pump-1, PUMP, Designs, Alpha Thalassemia/Mental Retardation Syndrome X-Linked Gene Mutation, Pi3k, ras85B, ras85D, experimental design, Endometrium Cancer, File Validated, c-Met Gene Amplification, p55alpha, D-ras-2, PR+, FMS-Like Tyrosine Kinase 2 Gene Rearrangement, Manufacturer Name, Endometrium Carcinoma, malignant neoplasm, Anti-Hepatitis B Core Antibody Positive, B7 Homolog 1 Positive, Beta 1 (88kD) Gene Mutation, Malignancies, Pi3K, PI3k, Positive, MCMTC, matrin activity, ATP, Carcinoma, PI3K68D, l(3)s1747, Anti-HBs Antibody Positive, TP53 Gene Mutation, PtdIns-3-kinase activity, Research Proposals, 1p/19q co-deletion, KIT Proto-Oncogene Tyrosine Protein Kinase Positive, v-Ha-ras Harvey Rat Sarcoma Viral Oncogene Homolog Gene Mutation, Metabolic Network, Positive Estrogen Receptor, vacuolar protein sorting 34, HBsAb Positive, 1-phosphatidylinositol 3-kinase activity, K-SAM Gene Mutation, Succinate Dehydrogenase Complex Flavoprotein Subunit A Positive, MMP 7, Personalized Medicine, Genetic Materials, p21[Ras1], dRAS1, Succinate Dehydrogenase Complex Iron Sulfur Subunit B Positive, Dras85D, KRAS2 Gene Mutation, Genetic Material, Clinical Data, Transphosphorylases, l(1)G0351, LD02673, Paired Domain Gene 8 Gene Rearrangement, p85alpha, c-Ha-ras, D-ras1, D-ras2, Programmed Cell Death 1 Ligand 1 Positive, ESR2 Positive, Dras64B, endometrial tumor, Hepatitis C RNA Positive, l(3)06677, Type 1, Identified, ocular pemphigus, Positive Laboratory Test Result, Paired Box 8 Gene Rearrangement, LCAM Gene Mutation, Patient, E-Cadherin Gene Mutation, l(1)G0127, Cistron, inherited genetic, p120-PI3K, Arc-1 Gene Mutation, N-SAM Gene Mutation, N-SAM Gene Rearrangement, CD274 Positive, Concurrent, KRAS-2 Gene Mutation, PDL1 Positive, Cancer Therapy, Benign Neoplasm, Gene, Pi3K_59F, KIT Positive, Scoring Method, Anti-HBc Antibody Positive, DmelCG9375, TERT Promoter Mutation, type I phosphatidylinositol kinase activity, KAL2 Gene Mutation, ECT1 Gene Rearrangement, phosphatidylinositol 3-kinase, dilute, l(1)G0388, Anoctamin-1 Positive, FGFR-3 Gene Mutation, reduced, Anti-Hepatitis B Virus Surface Antibody Positive, HIV test positive, l(1)G0380, sensitivity, Phosphotransferase, Dp110/PI3K, PI3K-68D/E, Erb-B2 Receptor Tyrosine Kinase Gene Mutation, Somatic, BFGFR Gene Rearrangement, Methodology, hotspot, Cancer of the Endometrium, dras1, Dm-ras-64B, Genetic, Malignancy, Coincident, Proposals, Fibroblast Growth Factor Receptor 3 Gene Mutation, Cadherin 1, E-Cadherin (Epithelial) Gene Mutation, HER2/neu Gene Mutation, PI3'K, BRCA1 Associated Protein 1 Gene Mutation, v-Kit Hardy-Zuckerman 4 Feline Sarcoma Viral Oncogene Homolog Positive, l(1)G0391, Ras 85D, Positive Lymph Node, MANUFACTURER, C-H-RAS Gene Mutation, OGD Gene Rearrangement, KAL2 Gene Rearrangement, Known, SDH1 Positive, ER Alpha Positive, UCHL2 Gene Mutation, RAD54L Gene Mutation, dP110, GNA-11 Gene Mutation, Inositol Phosphoglyceride, 6330412C24Rik, CEK Gene Rearrangement, p120, p110, Hepatitis C Antibody Positive, Formulation, Loss of Chromosomes 1p/19q, Cistrons, ESTRR Positive, Client, K-SAM Gene Rearrangement, Phosphotransferases, Inositol, Characteristic, Clinical Lot, del(1p/19q), EP(X)1093, Fibroblast Growth Factor Receptor 3 Gene Rearrangement, techniques, ESRA Positive, Proposal, Methods, ERBB2 Mutation, Basic, Phosphoinositide, ETV Family Rearrangement, tumour of endometrium, PI3K-59F, purpose, Hepatitis C Virus Antibody Positive, Beta-Catenin Gene Mutation, GA11 Gene Mutation, PI3K-Dp110, Paired Box Gene 8 Gene Rearrangement, TP2 Promoter Mutation, error, uterine metalloendopeptidase activity, Sequence Number, Source, Basis, ORAOV2 Positive, validated, p110gamma, Su(tor)3-2, Specified, BAP1 Mutation, c-K-ras Gene Mutation, Inositol Phospholipid, FGFR-1 Gene Mutation, P Health, Inclusive, Mitochondrial Positive, GenomefalseMMP-seq cell lines (FASTQ) - samplesMMP-seq cell lines (FASTQ)2017-07-26 15:39:25EGAD00001001107960624573554EGAC00001000055EGAS00001000674